PK/PD and Safety of CKD-382 vs D026 in Healthy Subjects

Phase 1, randomised, open-label trial of esomeprazole in gastroesophageal reflux disease (GERD) (6 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Area under the plasma drug concentration-time curve within a dosing interval at steady state and Percent decrease from baseline in integrated gastric acidity at 24 hours. Status: unknown.